The global metabotropic glutamate receptor 1 market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of depression and other neurological disorders, growing number of patients with autism spectrum disorder, and increasing demand for novel therapies for treatment-resistant depression.
The global metabotropic glutamate receptor 1 market is segmented on the basis of type (F311, JBPO0101, V0467558), application (depression, DiGeorge syndrome, infantile spasm), and region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa). North America accounted for the largest share in the global metabotropic glutamate receptor 1 market in 2018. This can be attributed to high prevalence rates of depression in this region as well as increased awareness about mental health issues among people living in North America.
- The Metabotropic Glutamate Receptor 1 market is driven by factors such as increasing prevalence of neurological disorders, growing number of clinical trials, and increasing research funding for the development of new drugs.
- Increasing prevalence of neurological disorders such as Alzheimer's disease and Parkinson's disease are driving the growth in the Metabotropic Glutamate Receptor 1 market.
- Growing number of clinical trials for Metabotropic Glutamate Receptor 1 drugs are also driving the growth in this market.
- Increasing research funding for development of new drugs is also driving the growth in this market.
Industry Growth Insights published a new data on “Metabotropic Glutamate Receptor 1 Market”. The research report is titled “Metabotropic Glutamate Receptor 1 Market research by Types (FC-311, JBPOS-0101, VU-0467558, Others), By Applications (Depression, DiGeorge Syndrome, Infantile Spasm, Others), By Players/Companies Aevi Genomic Medicine Inc, Biohaven Pharmaceutical Holding Company Ltd”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Metabotropic Glutamate Receptor 1 Market Research Report
By Type
FC-311, JBPOS-0101, VU-0467558, Others
By Application
Depression, DiGeorge Syndrome, Infantile Spasm, Others
By Companies
Aevi Genomic Medicine Inc, Biohaven Pharmaceutical Holding Company Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Metabotropic Glutamate Receptor 1 Market Report Segments:
The global Metabotropic Glutamate Receptor 1 market is segmented on the basis of:
Types
FC-311, JBPOS-0101, VU-0467558, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Depression, DiGeorge Syndrome, Infantile Spasm, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aevi Genomic Medicine Inc
- Biohaven Pharmaceutical Holding Company Ltd
Highlights of The Metabotropic Glutamate Receptor 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- FC-311
- JBPOS-0101
- VU-0467558
- Others
- By Application:
- Depression
- DiGeorge Syndrome
- Infantile Spasm
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metabotropic Glutamate Receptor 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metabotropic glutamate receptor 1 is a type of glutamate receptor that is responsible for mediating the effects of glutamate in the brain. This receptor is thought to play a role in regulating mood and cognitive function.
Some of the major companies in the metabotropic glutamate receptor 1 market are Aevi Genomic Medicine Inc, Biohaven Pharmaceutical Holding Company Ltd.
The metabotropic glutamate receptor 1 market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Metabotropic Glutamate Receptor 1 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Metabotropic Glutamate Receptor 1 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Metabotropic Glutamate Receptor 1 Market - Supply Chain
4.5. Global Metabotropic Glutamate Receptor 1 Market Forecast
4.5.1. Metabotropic Glutamate Receptor 1 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Metabotropic Glutamate Receptor 1 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Metabotropic Glutamate Receptor 1 Market Absolute $ Opportunity
5. Global Metabotropic Glutamate Receptor 1 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Type
5.3.1. FC-311
5.3.2. JBPOS-0101
5.3.3. VU-0467558
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Metabotropic Glutamate Receptor 1 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Application
6.3.1. Depression
6.3.2. DiGeorge Syndrome
6.3.3. Infantile Spasm
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Metabotropic Glutamate Receptor 1 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Metabotropic Glutamate Receptor 1 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Metabotropic Glutamate Receptor 1 Demand Share Forecast, 2019-2026
9. North America Metabotropic Glutamate Receptor 1 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Application
9.4.1. Depression
9.4.2. DiGeorge Syndrome
9.4.3. Infantile Spasm
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Type
9.7.1. FC-311
9.7.2. JBPOS-0101
9.7.3. VU-0467558
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Metabotropic Glutamate Receptor 1 Demand Share Forecast, 2019-2026
10. Latin America Metabotropic Glutamate Receptor 1 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Application
10.4.1. Depression
10.4.2. DiGeorge Syndrome
10.4.3. Infantile Spasm
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Type
10.7.1. FC-311
10.7.2. JBPOS-0101
10.7.3. VU-0467558
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Metabotropic Glutamate Receptor 1 Demand Share Forecast, 2019-2026
11. Europe Metabotropic Glutamate Receptor 1 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Application
11.4.1. Depression
11.4.2. DiGeorge Syndrome
11.4.3. Infantile Spasm
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Type
11.7.1. FC-311
11.7.2. JBPOS-0101
11.7.3. VU-0467558
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Metabotropic Glutamate Receptor 1 Demand Share, 2019-2026
12. Asia Pacific Metabotropic Glutamate Receptor 1 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Application
12.4.1. Depression
12.4.2. DiGeorge Syndrome
12.4.3. Infantile Spasm
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Type
12.7.1. FC-311
12.7.2. JBPOS-0101
12.7.3. VU-0467558
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Metabotropic Glutamate Receptor 1 Demand Share, 2019-2026
13. Middle East & Africa Metabotropic Glutamate Receptor 1 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Application
13.4.1. Depression
13.4.2. DiGeorge Syndrome
13.4.3. Infantile Spasm
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Metabotropic Glutamate Receptor 1 Market Size and Volume Forecast by Type
13.7.1. FC-311
13.7.2. JBPOS-0101
13.7.3. VU-0467558
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Metabotropic Glutamate Receptor 1 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Metabotropic Glutamate Receptor 1 Market: Market Share Analysis
14.2. Metabotropic Glutamate Receptor 1 Distributors and Customers
14.3. Metabotropic Glutamate Receptor 1 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aevi Genomic Medicine Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biohaven Pharmaceutical Holding Company Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
